Lebwohl, Mark, Melinda Gooderham, Richard B. Warren, Diamant Thaçi, Peter Foley, Alice B. Gottlieb, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, and Christopher EM Griffiths. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial”. SKIN The Journal of Cutaneous Medicine 7, no. 6 (November 13, 2023): s239. Accessed July 3, 2024. https://jofskin.org/33014/index.php/skin/article/view/2361.